

APC/Fire™ 750 anti-H2A.X Phospho (Ser139)

Catalog # / 3667105 / 25 tests
Size: 3667110 / 100 tests

Clone: 2F3


Isotype: Mouse IgG1, κ

Immunogen: Modified peptide

Reactivity: Human

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Nocodazole treated HeLa cells (24 hours) were fixed and permeabilized with cold 70% ethanol, then intracellularly stained with anti-H2A.X Phospho (Ser139) (clone 2F3) APC/Fire™ 750 (filled histogram) or mouse IgG1, κ APC/Fire™ 750 (open histogram).

Applications:

Applications: Intracellular Staining for Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Application Notes: **Additional reported applications (for the relevant formats of this clone) include:** immunohistochemistry on paraffin embedded sections², immunofluorescence microscopy³⁻⁹, Western blotting¹⁰⁻¹², and flow cytometry^{1,13}. Clone 2F3 cross-reacts with mouse⁴.

Intracellular staining protocol for Anti-H2A.X-Phosphorylated (Ser139) Antibody for Flow Cytometry

1. Prepare 70% absolute ethanol. Chill solution by storing at -20°C.
2. Prepare cells of interest.
3. Wash 1X with PBS, centrifuge at 350g for 5 min.
4. Discard the supernatant and vortex to loosen cell pellet.
5. Add pre-cooled 70% ethanol drop by drop, while vortexing.
6. Incubate at -20°C for 60 minutes.
7. Wash 3X.

**Application
References:**

1. Jha JC, et al. 2013. *J. Virol.* 87:5255. (FC) [PubMed](#)
2. Akbay A, et al. 2008. *Am J Pathol.* 173:536. (IHC) [PubMed](#)
3. Mochizuki K, et al. 2008. *J cell Sci.* 121:2148. (IF) [PubMed](#)
4. Xiao R, et al. 2007. *Mol Cell Biol.* 27:5393. (IF) [PubMed](#)
5. Rossi DJ, et al. 2007. *Nature.* 447:725. (IF) [PubMed](#)
6. Loidl J, et al. 2009. *Mol Cell Biol.* 20:2048. (IF) [PubMed](#)
7. Beels L, et al. 2009. *Circulation.* 120:1903. (IF) [PubMed](#)
8. Suzuki K, et al. 2010. *Nucleic Acids Res.* 38:e129. (IF) [PubMed](#)
9. Lukaszewicz A. 2010. *Chromasoma* Apr 27. [Epub ahead of print] (IF) [PubMed](#)
10. Yamada C, et al. 2010. *J. Biol. Chem.* 285:16693. (WB) [PubMed](#)
11. Bu Y, et al. 2010. *Biochem Biophys Res Commun.* 397:157. (WB) [PubMed](#)
12. Massignan T, et al. 2010. *J. Biol Chem.* 285:7752. (WB) [PubMed](#)
13. Banath JP, et al. 2010. *BMC Cancer* 10:4 (FC)
14. Zhang M., et al. 2011. *Cancer Res.* 23:7155. [PubMed](#)
15. Kuefner MA, et al. 2012. *Radiology* 264:59. [PubMed](#)
16. Yoshihara Y, et al. 2012. *Biochem Biophys Res Commun.* 421:57. [PubMed](#)
17. Titus S, et al. 2013. *Sci Transl Med.* 13:21. [PubMed](#)
18. Crown KN, et al. 2013. *G3.* 6:1927. [PubMed](#)
19. Schenkwein D, et al. 2013. *Nucleic Acids Res.* 41:e61. [PubMed](#)
20. Zhadanova NS, et al. 2014. *Mol Cell Biol.* 34:2786. [PubMed](#)
21. Horrell SA, et al. 2014. *Eukaryot Cell.* 13:1300. [PubMed](#)
22. Maya-Mendoza A, et al. 2015. *Mol Oncol.* 9:601. [PubMed](#)

Description: H2A.X is a 14 kD basal histone and a member of the H2 histone family. This nuclear protein is synthesized in the G1 and S phase of the cell cycle and is known to be important for DNA repair and maintaining genomic stability and for recombination between immunoglobulin switch regions. H2A.X becomes phosphorylated on serine 139 after double-stranded DNA breaks. Phosphorylated H2A.X promotes DNA repair and maintains genomic stability. The 2F3 monoclonal antibody reacts with phosphorylated human H2A.X (Ser139) and has been shown to be useful for Western blotting, immunofluorescence and flow cytometry.

**Antigen
References:**

1. Mannironi C, et al. 1989. *Nucleic Acids Res.* 17:9113.
2. Celeste A, et al. 2002. *Science* 296:922.
3. Bassing CH, et al. 2002. *Proc. Natl. Acad. Sci. USA* 99:8173.
4. Reina-San-Martin B, et al. 2003. *J. Exp. Med.* 197:1767.